Other Events
Show detailsHide details
8.01 Other Events
Yarrow Bioscience Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biotech developing YB-101, a potential first-in-class antibody therapy for Graves' disease and thyroid eye disease, two autoimmune conditions that attack the thyroid. Founded and incubated by investment firm RTW Investments, it merged with VYNE Therapeutics in 2026 and kept the Yarrow name. That name nods to the yarrow flower, a legendary healing herb said to have been used by Greek hero Achilles to treat soldiers' wounds.
8.01 Other Events
1.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.02 Results of Operations and Financial Condition · 3.02 Unregistered Sales of Equity Securities · 3.03 Material Modification to Rights of Security Holders · 5.01 Changes in Control of Registrant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing